| UDENYCA® ONBODYDetailsCancer, Chemotherapy-induced neutropenia |
Approved |
| YUSIMRY (CHS-1420) (Humira® Biosimilar (adalimumab)) (Anti-TNF)DetailsArthritis, Psoriasis, Inflammatory disease |
Approved |
| CIMERLI (CHS-201) (Lucentis biosimilar)DetailsWet age-related macular degeneration , Age-related macular degeneration, Eye disease |
Approved |
| LOQTORZI (Toripalimab) + ChemotherapyDetailsNasopharyngeal carcinoma |
Approved |
| UDENYCA® (pegfilgrastim-cbqv) BiosimilarDetailsCancer, Chemotherapy-induced neutropenia |
Approved |
| Toripalimab (anti-PD-1 antibody)(JUPITER-06) + ChemotherapyDetailsEsophageal Squamous Cell Carcinoma |
Phase 3 |
| LOQTORZI (Toripalimab) + INO 3112DetailsHPV+ oropharyngeal cancer, Cancer |
Phase 3 |
| Casdozokitug (casdozo) w/ atezolizumab & bevacizumabDetailsCancer, Hepatocellular carcinoma |
Phase 2 |
| Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1)DetailsNon-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s |
Phase 1/2 |
| Casdozokitug (casdozo)DetailsCancer, Non-small cell lung carcinoma |
Phase 1/2 |
| CHS-114 (SRF114)DetailsSolid tumor/s, Cancer |
Phase 1 |
| CHS-131DetailsMultiple sclerosis, Non-alcoholic steatohepatitis |
Failed |
| Toripalimab (CHS-305) Biosimilar (bevacizumab) + ChemotherapyDetailsCancer, Small cell lung cancer |
Failed |
| Toripalimab (CHS-305) Biosimilar (bevacizumab) + anti-TIGITDetailsNon-small cell lung carcinoma, Cancer |
Failed |
